Meta AnalysisID 2344
磷脂酰丝氨酸治疗儿童注意缺陷多动障碍（ADHD）的疗效：一项系统评价与Meta分析
CRD42018093188
What is the efficacy of phosphatidylserine supplementation in reducing symptoms of ADHD in children 6-18 years old?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2344
- Evidence Id
- 10902
- Core Evidence Id
- 10902
- Source Meta Analysis Id
- 2291
- Herb2 Meta Analysis Id
- HBMA002291
- Crd Id
- CRD42018093188
- Title
- The efficacy of phosphatidylserine in the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD): a systematic review and meta-analysis
- Review Question
- What is the efficacy of phosphatidylserine supplementation in reducing symptoms of ADHD in children 6-18 years old?
- Study Type Included
- Included studies will be randomized, controlled trials comparing phosphatidylserine to any type of control: placebo, wait list, or standard-of-care. Due to resource limitations, only studies available in English will be used. As mentioned above, only studies which include children diagnosed with ADHD via the DSM-IV or DSM-V will be considered. The DSM-IV was published in 1994; therefore, any study including children who were diagnosed before then will not be considered.
- Condition Being Studied
- ADHD is a widespread condition that can radically affect quality of life. In the US, 11% of children 4-17 years old have been diagnosed with ADHD. Children with ADHD are more likely to experience obesity, peer problems, emergency department admission, major injuries, expulsion from school, and lower GPAs. They are more likely to receive lower scores on standardized academic achievement tests, and less likely to attend or graduate from college. The annual societal cost of ADHD in the US is estimated to be $36-52 billion. The social, academic, and personal difficulties associated with pediatric ADHD can continue into adulthood and interfere with career, marriage, and health. Fifteen percent of children with ADHD will still have the disorder as adults and are at increased risk of substance abuse disorders, nicotine use, speeding violations, multiple marriages, and job loss. ADHD is also associated with an elevated rate of homelessness among males. Adults with ADHD are at increased risk of being victim or perpetrator of intimate partner violence, and are also at increased risk of suicide.
- Participant
- To be eligible, studies must involve children 6-18 years old with ADHD of any type, diagnosed via the DSM-IV or DSM-V by a qualified mental health professional. Diagnosis via previous editions will not be considered, because of the substantial change in the definition of ADHD between the DSM-III and the DSM-IV. Studies including participants with comorbid conditions will be remain eligible. Individuals with ADHD are at greater risk for other conditions, including depression and conduct disorders; including participants with comorbid conditions contributes to more externally valid results.
- Animal
- Human Disease Modelled
- Intervention
- Studies must involve phosphatidylserine supplementation from any source (bovine cortex, soy, sunflower, krill, squid, or other) for any length of time in any dosage. Though there are no limits on dose and duration, those parameters must be reported in the study.
- Comparator Control
- Included studies must compare phosphatidylserine to any type of control: placebo, wait list, or standard-of-care.
- Main Outcome
- Efficacy of phosphatidylserine in the treatment of pediatric ADHD. Studies will be eligible if they assess symptoms of ADHD or domains of ADHD (inattention or hyperactivity/impulsivity) using a validated scale. Scales must be used at baseline and then again at least once after the initiation of the intervention. Measures of effect Data collected from different time points will be broken into the following categories: Short intervention: <7 days Moderate-length intervention: 1-12 weeks Long intervention: 12 weeks+
- Outcome Measure
- Additional Outcome
- If available, data about adverse outcomes and attrition rates will also be collected.
- Study Method
- Intervention, Meta-analysis, Qualitative synthesis, Systematic review
- Keyword
- Attention Deficit Disorder with Hyperactivity; Child; Humans; Phosphatidylserines
- Contact
- Alisha Bruton [email protected]
- Organisational Affiliation
- National University of Natural Medicine (NUNM); Helfgott Research Institute NUNM.edu
- Funding Source
- None.
- Other Selection Criteria
- Final Publication
- Bruton A, Nauman J, Hanes D, Gard M, Senders A. Phosphatidylserine for the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. J Altern Complement Med. 2021 Feb 4. doi: 10.1089/acm.2020.0432. Epub ahead of print. PMID: 33539192. https://PubMed.ncbi.nlm.nih.gov/33539192/
- Same Topic Review
- Published Protocol
- https://www.crd.york.ac.uk/PROSPEROFILES/93188_PROTOCOL_20180406.pdf
- Review Type
- Language
- English
- Country
- United States of America
- Review Stage
- Review Completed published
- First Submission Date
- 2018-04-06
- Registration Date
- 2018-04-18
- Anticipated Start Date
- 2018-04-10
- Anticipated Completion Date
- 2018-09-10
- Title Cn
- 磷脂酰丝氨酸治疗儿童注意缺陷多动障碍（ADHD）的疗效：一项系统评价与Meta分析
- Title En
- The efficacy of phosphatidylserine in the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD): a systematic review and meta-analysis
- Bilingual Status
- complete